Recently, Opdualag, a fixed-dose combination of anti-LAG-3 and anti-PD-1, has shown significant therapeutic efficacy and was approved for treating melanoma in adults and children, marking LAG-3 as the third immune checkpoint pathway approved for clinical use by the FDA [22]. The gene discussed is LAG3; the disease is melanoma.